Biotechnology

Small biotech Veru Inc. is betting its future on improving blockbuster weight-loss drugs, targeting the hidden cost of muscle loss in a billion-dollar market.

A novel partnership aims to create the first drug for ReNU syndrome, a condition found in 2024, potentially redefining rare disease drug development.

Pacira BioSciences de-risks its promising knee osteoarthritis gene therapy by solving the manufacturing puzzle, a key step from lab to market for millions.

AsymBio breaks ground on a Shanghai R&D center, integrating AI and manufacturing to slash drug development timelines. Is this the end of the CDMO handoff?

With a new CMO and fresh funding, Spero Therapeutics is betting big on its immunology asset SP001. Can Dr. Zack guide it to success in a competitive field?

A breakthrough trial for a rare genetic disorder unlocks $50M in funding. We explore the novel RNA science, the savvy investment, and why it's all happening in Australia.

Following a strategic merger and a $200M financing round, Yarrow Bioscience is advancing a novel drug for autoimmune thyroid disease. But can it disrupt a market dominated by incumbents?

With the hire of Abecma veteran Dr. Steven Bernstein, Liberate Bio signals its readiness to take its 'off-the-shelf' CAR-M therapy into the clinic.

A federal jury found investment firm RA Capital willfully misappropriated trade secrets from Yale, a stark reminder for investors of the risks of lax IP due diligence.

Promising early data for BBT001 suggests a potent combination of rapid relief and quarterly dosing, but can the biotech startup navigate the long road from pilot to production?

With its $2.2B acquisition of Forte, argenx adds a first-in-class antibody, FB102, expanding its Vision 2030 strategy to redefine autoimmune care.

A positive EMA opinion for Minoryx's NEZGLYAL offers the first-ever drug therapy for a fatal childhood disease, highlighting a key regulatory pathway.

Vir Biotechnology's CFO departs, triggering a 7% stock slide. Can interim chief Brent Sabatini, an internal veteran, steady the ship amid strategic shifts?

Radiopharm Theranostics secures crucial funding for its promising oncology pipeline, but a sharp stock drop reveals deep investor concerns about dilution.

Samsung Epis Holdings reports solid growth driven by its biosimilar portfolio, but the real story is its strategic pivot to next-gen cancer drugs and global expansion.

Ipsen's BOLD trial for biliary atresia failed, a blow to families. But in the data from this setback lies a critical roadmap for future research.

A Tokyo innovator just hit Nasdaq via a SPAC. Is its vertically integrated model the key to unlocking the $67B longevity market or just another biotech gamble?

With 14,000 new biotech jobs on the horizon, a new AI-powered lab coach aims to train the next generation of scientists, starting in underserved high schools.

A series of decisive legal victories in the U.S. and Europe has given food giant Danone a powerful grip on the future of a key gut health microbe.